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Abstract 
 
Background. A role for radiotherapy after mastectomy for ductal carcinoma in situ 
(DCIS) is unclear.  Using a prospective audit of DCIS detected through the NHS Breast 
Screening Programme we sought to determine a rationale for the use of 
postmastectomy radiotherapy for DCIS. 
 
Methods. Over a nine year period, from 9,972 patients with screen-detected DCIS and 
complete surgical, pathology, radiotherapy and follow up data, 2,944 women 
underwent mastectomy for DCIS of whom 33 (1.12%) received radiotherapy. 
 
Results. Use of post mastectomy radiotherapy  was significantly associated with a 
close (<1mm) pathology margin, particularly  (χ2(1) 95.81; p<0.00001), DCIS size (χ2 (3) 
16.96; p<0.001) and the presence of microinvasion (χ2(1) 3.92; p<0.05).  At median 
follow up 61 months, no woman who received radiotherapy had an ipsilateral further 
event, and only 1/33 women (3.0%) had a contralateral event.  Of the women known 
not to have had radiotherapy post mastectomy, 45/2,894 (1.6%) had an ipsilateral 
further event and 83 (2.9%) had a contralateral event.    
 
Conclusion: For DCIS treated by mastectomy, a close (<1mm) margin, large tumour 
size and microinvasion, may merit radiotherapy to reduce ipsilateral recurrence. 
 
 
  
Introduction 
 
The prognosis for screen-detected ductal carcinoma in situ (DCIS) is excellent and 
within the UK NHS Breast Screening Programme (NHSBSP) relative breast cancer-
specific mortality is no different to an unaffected population (1).  Mastectomy is still 
commonly performed for DCIS and is in the great majority of cases curative.  Local 
recurrence after mastectomy is rare (2). 
 
In the context of early invasive breast cancer, rather than DCIS, radiotherapy is almost 
always recommended after breast conserving surgery (BCS) and removes around 70% 
of the risk of recurrence (3). Radiotherapy following mastectomy for invasive disease 
is also recommended if recurrence risk is high. The Early Breast Cancer Trialists’ 
Collaborative Group (EBCTCG) overview reports that patients with positive lymph 
nodes have a 23% local recurrence risk without radiotherapy and a 6% risk if 
radiotherapy is given (risk reduction 74%) (3).  Following BCS for DCIS, radiotherapy 
reduces the risk of (invasive and in situ) recurrence by 54% (4), but is utilised 
infrequently after mastectomy (5,6,7).  
 
Although there are retrospective data (5,6,7), no prospective studies have examined 
the effects of post-mastectomy radiotherapy (PMRT) in DCIS.  In order to understand 
the possible reasons why PMRT may be recommended for DCIS after mastectomy, the 
prospectively collected NHS Breast Screening Programme audit data were 
interrogated to compare demographic and histopathological variables with outcomes 
in women receiving radiotherapy and those who did not post mastectomy.  
 
  
Methods 
 
The prospective audit of NHS breast screen-detected non-invasive breast carcinoma 
and atypical hyperplasia (the Sloane Project, named after eminent pathologist John 
Sloane) accrued patients from 2003-2012. Eighty nine percent of NHS breast screening 
units geographically spread across the UK participated in the audit, and data were 
captured on 40% of all women with screen detected non-invasive neoplasia. Data 
capture at source was through manually completed radiology, surgery, pathology and 
radiotherapy forms, collated onto a single data base. The Sloane Project is 
administered by the West Midlands Cancer Screening Quality Assurance Reference 
Centre, part of Public Health England. A Steering Committee comprises surgeons, 
pathologists, radiologists, oncologists and a patient advocate. Further details of the 
Sloane Project are available through the website (www.sloaneproject.org.uk). 
 
The prospectively collected Sloane Project database was examined retrospectively to 
identify women treated for DCIS who had undergone mastectomy. Data were 
extracted including the age of diagnosis, histological features, use of and recorded 
indication for PMRT.  Further events were identified by matching the cases by NHS 
number and date of birth to information provided by Sloane contacts in NHS breast 
screening units and to routinely collected datasets, which included Cancer Waiting 
Times, Hospital Episode Statistics, the English National Radiotherapy Dataset, the 
English Cancer Analysis System/National Cancer Registration Service and datasets 
held by the Information Services Division Scotland.  The census date for further events 
and deaths was 31 December 2012; giving a median follow up time of 61 months.  
Women who died of breast cancer but who had no further events recorded were 
deemed to have had distant metastases on the date they died.  If there was no 
evidence of women having a contralateral breast cancer diagnosis, distant events 
were deemed to be ‘ipsilateral distant events’. 
 
Statistics 
 
Pearson’s chi-squared test was used to test for a significant difference between those 
receiving radiotherapy or not receiving radiotherapy following mastectomy according 
to age at diagnosis, tumour size, final margin size, cytonuclear grade of the DCIS, 
presence of microinvasion and presence of comedo necrosis.  A chi-squared 
probability of less than or equal to 0.05 was interpreted as the cut-off point at which 
there was a significant difference and thus the point at which the null hypothesis could 
be rejected.  
 
  
Results 
 
12,838 women with a diagnosis of screen-detected DCIS in the 9-year period between 
1/4/2003 and 31/3/2012 were prospectively entered into the Sloane Project 
database;  9,972 (78%) women had complete and informative data in relation to 
surgical operation, radiotherapy utilisation, DCIS size and/or margin status and follow-
up (Figure 1). Of these 9,972 surgically treated women, 2,944 (30%) underwent 
mastectomy as their final surgical procedure, and 33 (1.12%) of these women were 
confirmed to have received post-operative radiotherapy (Figure 1).  The 33 women 
who received radiotherapy were treated in 16 different NHS breast screening units. 
 
The use of PMRT was related to margin status and this was statistically significant 
when the margin was <1mm (χ2 (1) =95.81 p<0.00001).  Of the 925 (31%) women 
with data on margin status, 16% (16/99) with final margin status <1mm received 
radiotherapy  and  4% (3/78) with margin status 1-<2mm received radiotherapy. There 
was no association between size of margin and tumour recurrence in the women 
treated by mastectomy for DCIS. There was also a significant association with 
increasing tumour size (χ2 (3) = 16.96, p<0.001; for tumours with known size), with 
women who had DCIS >50mm being more likely to receive radiotherapy (χ2 (1) = 8.60, 
p<0.01). There also appeared to be a borderline significant association with the 
presence of microinvasion (χ2 (1) = 3.92, p<0.05; for tumours with known 
microinvasive status).  Although the use of radiotherapy was lower in women with low 
cytonuclear grade tumours and higher in those with tumours with comedo necrosis 
present, these differences were not statistically significant (Table 1).  There was no 
significant association of radiotherapy use with patient age.   
 
No woman who received radiotherapy had an ipsilateral further event (defined as 
ipsilateral chest wall, ipsilateral axilla or distant metastatic disease in the absence of a 
contralateral breast cancer) at median follow up 61 months, and only 1 woman had a 
contralateral breast cancer (Table 2).  However, 26 (0.9%) of the women who were 
known not to have had radiotherapy had an ipsilateral locoregional event (23 had an 
ipsilateral breast event and 3 had an ipsilateral nodal event) and 19 (0.7%) had a 
distant (metastatic) event.  A further 83 women (2.9%) who were known not to have 
had radiotherapy had a contralateral breast cancer.  The majority (24/26; 92%) of the  
women with locoregional ipsilateral events had invasive recurrencecancer (21 had an 
invasive ipsilateral breast event and 3 had an invasive ipsilateral nodal event).  No 
significant difference was seen between the frequencies of recurrencefurther events 
betweenin women treated with radiotherapy RT treated and those known not to have 
beenpatietns not treated with radiotherapyRT untreated forin non recurrence no 
further events, contralateral recurrenceevents, ipsilateral recurrenceevents andor 
metastasis ((χ2 (9) = 0.209, p=0.99).   Of the women who had locoregional events, 
19/26 (73%) had a high cytonuclear grade primary, 21/26 (81%) had comedo necrosis 
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in their primary tumour and 8/26 (31%) had a primary DCIS over 50mm in diameter.  
Of the 19 women with distant events, 15/19 (79%) had a high cytonuclear grade 
primary, 15/19 (79%) had comedo necrosis in their primary tumour and 8/19 (42%) 
had a primary tumour with a size greater than 50mm.  The majority (32/45) of 
ipsilateral further events in the no radiotherapy group occurred in women where 
margin status was not recorded.  Of the recurrencesfurther events (131), 12 showed 
micro- invasion (9.16%). 
 
Discussion 
 
There have been no randomised trials (nor are there likely to be) addressing the use 
of radiotherapy after mastectomy for DCIS. This large, prospective, audit has 
confirmed that few women (1.12%) with screen-detected DCIS receive PMRT.  Within 
this context, the strongest association was with margin status recorded for the use of 
radiotherapy (5), presumably due to the risk of local recurrence in the view of the 
surgeon/radiotherapist caring for the patient. The current audit has the advantage of 
large numbers of patients with screen-detected DCIS and median 61 months follow 
up. However, the partially complete data, low use of radiotherapy and non-
randomised data reflect the imperfections of clinical audit data. 
 
Local recurrence after mastectomy for DCIS has been reported, but is rare, and may 
be followed by metastatic disease (8), but is rare.  While recurrence may occur after 
breast conservation for DCIS, over 15 years or more from the original treatment (11), 
local recurrence with longer term follow up after mastectomy may be correspondingly 
higher than generally reported.  However, given that most case series avoid 
radiotherapy in all, or almost all, cases of DCIS treated with mastectomy (5), chest wall 
recurrence after post mastectomy radiotherapy for DCIS has only rarely been reported 
(6).  A meta-analysis of published studies reported a 1.4% recurrence rate (of further 
DCIS or mastectomy) after mastectomy for DCIS (2). Others have shown a 1% local 
recurrence at around 6 years of follow up, unchanged over 2 decades (8, 9,10) similar 
to the recurrence rate reported here at 5 years.   
 
There are limited data on the identification of patients who are at increased risk of 
recurrence of carcinoma after mastectomy for DCIS. Rashtian et al studied the 
consequences of close or positive margins after mastectomy for DCIS (12).  From an 
original cohort of 574 patients, 80 patients who did not receive radiotherapy were 
identified with margins of <10mm, 6 (7.5%) of these patients developed local 
recurrence at a median follow-up of 61 months.  Of these 6 patients, 5 originally had 
DCIS with margins of excision of 2mm or less, 5 were high grade disease, 5 had comedo 
necrosis, and all were under 60 years of age. 5/31 (16%) cases with resection margins 
less than or equal to 2mm developed local recurrence, comparable with the data 
presented here.  All of the recurrences were invasive, and 3 patients developed 
metastatic disease.  Pathological review of the original mastectomy blocks did not 
identify any invasive disease at the time of diagnosis.  In contrast, it has been  reported 
(10) that margin status was only a significant factor for recurrence for patients treated 
with BCS and not after mastectomy, leading others to suggest that the risk of chest 
wall recurrence was too low to recommend adjuvant radiotherapy (13). 
 
The majority of screen-detected DCIS studied here was high grade, in keeping with 
current UK quality assured pathology (?ref needed). There may be a disparity between 
different national practices, or proportions of patients entering a clinical trial - for 
example only 37% patients had high grade DCIS in the NSABP B-17 trial. The potential 
over-treatment of DCIS, use of patient and healthcare resources and the 
complications of radiotherapy (14,15) suggests the need to identify biomarkers for the 
minority of women who are likely tomight benefit from PMRT. 
 
This prospective  audit of screen detected DCIS demonstrates the infrequent use of 
PMRT for DCIS in routine clinical practice. Positive margin status and high grade 
disease appear to be used as potential indications for PMRT.  Further follow up within 
this and other large datasets of patients treated for DCIS should clarify possible 
indications forPMRT. 
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Figure 1:  Case consort diagram 
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Table 1:  Use of post mastectomy radiotherapy (%)  
 
Parameter 
Radiotherapy (RT) 
No. (%) RT 
not given 
No. (%)  
RT given 
Given 
No. (%) RT 
unknown 
Total no. (%) 
Age at diagnosis (years) 
<50 93 (100.00) 0 (0.00)  0 (0.00) 93 (3.16) 
50-64 2054 (98.32) 26 (1.24) 9 (0.43) 2089 (70.96) 
65-70 622 (98.11) 5 (0.79) 7 (1.10) 634 (21.54) 
71-73 64 (96.97) 2 (3.03) 0 (0.00) 66 (2.24) 
74+ 61 (98.39) 0 (0.00)  1 (1.61) 62 (2.11) 
Total 2894 (98.30) 33 (1.12) 17 (0.58) 2944 (100.00)   
Tumour size (mm) 
0-20 707 (98.88) 4 (0.56) 4 (0.56) 715 (24.29) 
>20-50 1406 (98.46) 14 (0.91) 9 (0.63) 1428 (48.51) 
>50-100 669 (97.66) 12 (1.75) 4 (0.58) 685 (23.27) 
>100 70 (94.59) 4 (5.41) 0 (0.00) 74 (2.51) 
Unknown  42 (100.00) 0 (0.00)  0 (0.00) 42 (1.43) 
Total 2894 (98.30) 33 (1.12) 17 (0.58) 2944 (100.00)   
Final margin distance (mm) 
0 29 (72.50) 11 (27.50) 0 (0.00) 40 (1.36) 
>0 - <1 54 (91.53) 5 (8.47) 0 (0.00) 59 (2.00) 
1 - <2 74 (94.87) 3 (3.85) 1 (1.28) 78 (2.65) 
2 - <5 138 (98.57) 1 (0.71) 1 (0.71) 140 (4.76) 
5 -– 10 196 (98.99) 0 (0.00)  2 (1.01) 198 (6.73) 
>10 408 (99.51) 1 (0.24) 1 (0.24) 410 (13.93) 
Unknown 1995 (98.81) 12 (0.59) 12 (0.59) 2019 (68.58) 
Total 2894 (98.30) 33 (1.12) 17 (0.58) 2944 (100.00) 
Cytonuclear grade of DCIS 
Low 138 (100.00) 0 (0.00)  0 (0.00) 138 (4.69) 
Intermediate 572 (98.11) 4 (0.69) 7 (1.20) 583 (19.80) 
High 2184 (98.25) 29 (1.30) 10 (0.45) 2223 (75.51) 
Total 2894 (98.30) 33 (1.12) 17 (0.58) 2944 (100.00) 
Microinvasion present 
Yes 251 (96.91) 6 (2.32) 2 (0.77) 259 (8.80) 
No 2617 (98.49) 26 (0.98) 14 (0.53) 2657 (90.25) 
Unknown 26 (92.86) 1 (3.57) 1 (3.57) 28 (0.95) 
Total 2894 (98.30) 33 (1.12) 17 (0.58) 2944 (100.00) 
Comedo necrosis present 
Yes 2085 (98.49) 24 (1.13) 8 (0.38) 2117 (71.91) 
No 647 (98.48) 6 (0.91)  4 (0.61) 657 (22.32) 
Unknown 162 (95.29) 3 (1.76)  5 (2.94) 170 (5.77) 
TOTAL 2894 (98.30) 33 (1.12) 17 (0.58) 2944 (100.00) 
 
Table 2   Variation in ipsilateral (ipsilateral chest wall, ipsilateral axilla or metastatic disease in the 
absence of a contralateral cancer) and contralateral further events with radiotherapy and margin status 
for women treated with mastectomy (further events before 31/12/12) 
     
                
Final 
margin 
(mm) 
Radiotherapy not given Radiotherapy given Radiotherapy Unknown 
No. All 
Mx 
cases 
No. (%) 
Ipsi-
lateral 
loco-
regional 
No. (%) 
All ipsi-
lateral 
No. (%) All 
contra-
lateral 
No. No 
further 
event 
before 
31/12/12 
Total 
No. 
RT 
not 
given 
No. (%) 
All ipsi-
lateral 
No. (%) 
All 
contra-
lateral 
No. No 
further 
event 
before 
31/12/12 
Total 
No. 
RT 
given 
No. (%) 
Ipsi-
lateral 
loco-
regional 
 
No. (%) 
All ipsi-
lateral 
No. (%) 
All 
contra-
lateral 
No. No 
further 
event 
before 
31/12/12 
Total No. 
Unknown 
RT 
0 1 (3.45) 2 (6.90) 1 (3.45) 26 29 0 (0.00) 1 (9.09) 10 11 0 (0.00) 0 (0.00) 0 (0.00) 0 0 40 
>0 - <1 0 (0.00) 1 (1.85) 0 (0.00) 53 54 0 (0.00) 0 (0.00) 5 5 0 (0.00) 0 (0.00) 0 (0.00) 0 0 59 
1 - <2 0 (0.00) 0 (0.00) 2 (2.70) 72 74 0 (0.00) 0 (0.00) 3 3 0 (0.00) 0 (0.00) 0 (0.00) 1 1 78 
2 - <5 2 (1.45) 4 (2.90) 3 (2.17) 131 138 0 (0.00) 0 (0.00) 1 1 0 (0.00) 0 (0.00) 1 (100) 0 1 140 
5 - 10 1 (0.51) 2 (1.02) 4 (2.04) 190 196 0 (0.00) 0 (0.00) 0 0 0 (0.00) 0 (0.00) 0 (0.00) 2 2 198 
>10 2 (0.49) 4 (0.98) 14 (3.42) 390 408 0 (0.00) 0 (0.00) 1 1 0 (0.00) 0 (0.00) 0 (0.00) 1 1 410 
Unknown 20 (1.02) 32 (1.60) 59 (2.96) 1904 1995 0 (0.00) 0 (0.00) 12 12 1 (8.33) 1 (8.33) 0 (0.00) 11 12 2019 
Total  26 (0.90) 45 (1.55) 83 (2.87) 2766 2894 0 (0.00) 1 (3.03) 32 33 1 (5.88) 1 (5.88) 1 (5.88) 15 17 2944 
 
 
 
 
